Found: 22
Select item for more details and to access through your institution.
Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-12056-0
- By:
- Publication type:
- Article
Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
- Published in:
- 2012
- By:
- Publication type:
- journal article
OS05.3.A Temporal muscle thickness as surrogate parameter of sarcopenia in newly diagnosed glioblastoma patients:translational imaging analysis of the CENTRIC EORTC 26071-22072 and CORE trials.
- Published in:
- 2021
- By:
- Publication type:
- Abstract
OS05.2.A MGMT promoter status in IDH1/2 mutant anaplastic astrocytoma patients assessed by DNA methylation profiling and qMS-PCR: a report from the EORTC Brain Tumor Group.
- Published in:
- Neuro-Oncology, 2021, v. 23, p. ii6, doi. 10.1093/neuonc/noab180.019
- By:
- Publication type:
- Article
PL03.4.A Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period.
- Published in:
- Neuro-Oncology, 2021, v. 23, p. ii2, doi. 10.1093/neuonc/noab180.006
- By:
- Publication type:
- Article
P14.54 Association of EGFR Expression and Copy Number with Outcome in Depatux-m (ABT-414) Randomized Phase II Study of the EORTC Brain Tumor Group.
- Published in:
- Neuro-Oncology, 2019, v. 21, p. iii79, doi. 10.1093/neuonc/noz126.289
- By:
- Publication type:
- Article
P14.41 Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC-26101 trial.
- Published in:
- Neuro-Oncology, 2019, v. 21, p. iii76, doi. 10.1093/neuonc/noz126.276
- By:
- Publication type:
- Article
P14.124 EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.
- Published in:
- Neuro-Oncology, 2019, v. 21, p. iii98, doi. 10.1093/neuonc/noz126.359
- By:
- Publication type:
- Article
P11.08 Defining EGFR amplification status for clinical trial inclusion.
- Published in:
- Neuro-Oncology, 2019, v. 21, p. iii43, doi. 10.1093/neuonc/noz126.154
- By:
- Publication type:
- Article
OS7.4 Calculating the net clinical benefit in brain tumor clinical trials by combining survival and health-related quality of life data using two methods: quality adjusted survival effect sizes (QASES) and joint modelling (JM).
- Published in:
- Neuro-Oncology, 2019, v. 21, p. iii14, doi. 10.1093/neuonc/noz126.047
- By:
- Publication type:
- Article
OS7.2 Measuring change in health-related quality of life: the added value of analysis on the individual patient level in glioma patients in clinical decision making.
- Published in:
- Neuro-Oncology, 2019, v. 21, p. iii14, doi. 10.1093/neuonc/noz126.045
- By:
- Publication type:
- Article
PL3.3 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.
- Published in:
- Neuro-Oncology, 2019, v. 21, p. iii3, doi. 10.1093/neuonc/noz126.006
- By:
- Publication type:
- Article
PL3.2 Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).
- Published in:
- Neuro-Oncology, 2019, v. 21, p. iii2, doi. 10.1093/neuonc/noz126.005
- By:
- Publication type:
- Article
P01.066 Patients with EGFR amplification but without EGFRvIII expression have improved benefit compared to those with EGFRvIII expression in samples of the INTELLANCE 2/EORTC 1410 randomized phase II trial.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. iii244, doi. 10.1093/neuonc/noy139.108
- By:
- Publication type:
- Article
P01.052 Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux -M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).
- Published in:
- Neuro-Oncology, 2018, v. 20, p. iii241, doi. 10.1093/neuonc/noy139.094
- By:
- Publication type:
- Article
P01.032 Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. iii235, doi. 10.1093/neuonc/noy139.074
- By:
- Publication type:
- Article
OS4.6 Does radiation target volume affect health-related quality of life in patients with low grade glioma on the short-term? - a secondary analysis of the EORTC 22033–26033 trial.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. iii223, doi. 10.1093/neuonc/noy139.031
- By:
- Publication type:
- Article
Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.
- Published in:
- British Journal of Cancer, 2012, v. 107, n. 4, p. 639, doi. 10.1038/bjc.2012.328
- By:
- Publication type:
- Article
A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.
- Published in:
- International Journal of Cancer, 2016, v. 138, n. 6, p. 1538, doi. 10.1002/ijc.29898
- By:
- Publication type:
- Article
Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article